Henry Xiong - Concepedia

Author

Henry Xiong

The University of Texas MD Anderson Cancer Center

Also Known As

H. Xiong, Haiwei Xiong, Hao Xiong, Henry Xiong, Vladimir Yareshko

Publications

2.6K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Center for Cancer and Blood Disorders Taiho Pharmaceutical (Japan)Istituti di Ricovero e Cura a Carattere Scientifico Florida Cancer Specialists & Research Institute

About

Henry Xiong is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	787
2	Health Sciences	3	3	125
3	Hepatology	2	2	566
4	Cell Biology	1	1	61
5	Immunology	1	1	32

Henry Xiong

Publications

Citations

H-Index

Page 1

	Year	Citations
Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head Gauri R. Varadhachary, Robert A. Wolff, Christopher H. Crane, Journal of Clinical Oncology	2008	466
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial Shukui Qin, Minshan Chen, Ann‐Lii Cheng, The Lancet Surgical OncologyHepatologyMedicinePathologyHigh-risk Hepatocellular Carcinoma	2023	415
Aggresome Disruption: A Novel Strategy to Enhance Bortezomib-Induced Apoptosis in Pancreatic Cancer Cells Steffan T. Nawrocki, Jennifer S. Carew, Maria Simona Pino, Cancer Research	2006	241
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies Milind Javle, Rachna T. Shroff, Henry Xiong, BMC Cancer	2010	164
Yttrium 90 Resin Microspheres for the Treatment of Unresectable Colorectal Hepatic Metastases after Failure of Multiple Chemotherapy Regimens: Preliminary Results Ravi Murthy, Henry Xiong, Rodolfo Núñez, Journal of Vascular and Interventional Radiology Surgical OncologyHepatologyMedicineHepatobiliary TumorColorectal Cancer	2005	151
Adjuvant <i>nab</i> -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial Margaret A. Tempero, Uwe Pelzer, Eileen M. O’Reilly, Journal of Clinical Oncology	2022	120
Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM) Herbert I. Hurwitz, Benjamin Tan, James A. Reeves, The Oncologist	2018	89
Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors Michael J. Overman, Gauri Varadhachary, Scott Kopetz, Investigational New Drugs 5-Day-per-week ScheduleSolid TumorsMedicineCancer ManagementPharmacotherapy	2008	78
Phase I Clinical Study of Three Times a Day Oral Administration of TAS-102 in Patients with Solid Tumors Michael J. Overman, Scott Kopetz, Gauri Varadhachary, Cancer Investigation	2008	64
Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts Chandrajit P. Raut, Steffan T. Nawrocki, Laura M. Lashinger, Cancer Biology & Therapy Pge2 ProductionTumor XenograftsEndothelial CellsChemoprevention StrategyCell Death	2004	61

Page 1